Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

Charles L Daley^{1

2}, Jonathan M Iaccarino³, Christoph Lange^{4

5

6

7}, Emmanuelle Cambau⁸, Richard J Wallace⁹, Claire Andrejak^{10

11}, Erik C Böttger¹², Jan Brozek¹³, David E Griffith¹⁴, Lorenzo Guglielmetti^{8

15}, Gwen A Huitt^{1

2}, Shandra L Knight¹⁶, Philip Leitman¹⁷, Theodore K Marras¹⁸, Kenneth N Olivier¹⁹, Miguel Santin²⁰, Jason E Stout²¹, Enrico Tortoli²², Jakko van Ingen²³, Dirk Wagner²⁴, Kevin L Winthrop²⁵

Affiliations

¹ Department of Medicine, National Jewish Health, Denver, Colorado, USA.
² Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
³ Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts, USA.
⁴ Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
⁵ German Center for Infection Research (DZIF), Clinical Tuberculosis Unit, Borstel, Germany.
⁶ Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany.
⁷ Department of Medicine, Karolinska Institute, Stockholm, Sweden.
⁸ National Reference Center for Mycobacteria and Antimycobacterial Resistance, APHP -Hôpital Lariboisière, Bacteriology; Inserm, University Paris Diderot, IAME UMR1137, Paris, France.
⁹ Mycobacteria/Nocardia Laboratory, Department of Microbiology, The University of Texas Health Science Center, Tyler, Texas, USA.
¹⁰ Respiratory and Intensive Care Unit, University Hospital Amiens, Amiens, France.
¹¹ EA 4294, AGIR, Jules Verne Picardy University, Amiens, France.
¹² Institute of Medical Microbiology, National Reference Center for Mycobacteria, University of Zurich, Zurich, Switzerland.
¹³ Department of Clinical Epidemiology & Biostatistics, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada.
¹⁴ Pulmonary Infectious Disease Section, University of Texas Health Science Center, Tyler, Texas, USA.
¹⁵ Team E13 (Bactériologie), Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche 7, INSERM, IAME UMR1137, Paris, France.
¹⁶ Library and Knowledge Services, National Jewish Health, Denver, Colorado, USA.
¹⁷ NTM Info & Research, Miami, Florida, USA.
¹⁸ Department of Medicine, University of Toronto and University Health Network, Toronto, Ontario, Canada.
¹⁹ Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA.
²⁰ Service of Infectious Diseases, Bellvitge University Hospital-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
²¹ Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, North Carolina, USA.
²² Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
²³ Radboud Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
²⁴ Division of Infectious Diseases, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
²⁵ Divisions of Infectious Diseases, Schools of Public Health and Medicine, Oregon Health and Science University, Portland, Oregon, USA.

PMID: 32797222
PMCID: PMC7768745
DOI: 10.1093/cid/ciaa1125

Practice Guideline

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

Charles L Daley et al. Clin Infect Dis. 2020.

. 2020 Aug 14;71(4):905-913.

doi: 10.1093/cid/ciaa1125.

Authors

Affiliations

¹ Department of Medicine, National Jewish Health, Denver, Colorado, USA.
² Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
³ Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts, USA.
⁴ Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
⁵ German Center for Infection Research (DZIF), Clinical Tuberculosis Unit, Borstel, Germany.
⁶ Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany.
⁷ Department of Medicine, Karolinska Institute, Stockholm, Sweden.
⁸ National Reference Center for Mycobacteria and Antimycobacterial Resistance, APHP -Hôpital Lariboisière, Bacteriology; Inserm, University Paris Diderot, IAME UMR1137, Paris, France.
⁹ Mycobacteria/Nocardia Laboratory, Department of Microbiology, The University of Texas Health Science Center, Tyler, Texas, USA.
¹⁰ Respiratory and Intensive Care Unit, University Hospital Amiens, Amiens, France.
¹¹ EA 4294, AGIR, Jules Verne Picardy University, Amiens, France.
¹² Institute of Medical Microbiology, National Reference Center for Mycobacteria, University of Zurich, Zurich, Switzerland.
¹³ Department of Clinical Epidemiology & Biostatistics, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada.
¹⁴ Pulmonary Infectious Disease Section, University of Texas Health Science Center, Tyler, Texas, USA.
¹⁵ Team E13 (Bactériologie), Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche 7, INSERM, IAME UMR1137, Paris, France.
¹⁶ Library and Knowledge Services, National Jewish Health, Denver, Colorado, USA.
¹⁷ NTM Info & Research, Miami, Florida, USA.
¹⁸ Department of Medicine, University of Toronto and University Health Network, Toronto, Ontario, Canada.
¹⁹ Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA.
²⁰ Service of Infectious Diseases, Bellvitge University Hospital-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
²¹ Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, North Carolina, USA.
²² Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
²³ Radboud Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
²⁴ Division of Infectious Diseases, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
²⁵ Divisions of Infectious Diseases, Schools of Public Health and Medicine, Oregon Health and Science University, Portland, Oregon, USA.

PMID: 32797222
PMCID: PMC7768745
DOI: 10.1093/cid/ciaa1125

Abstract

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

Keywords: Mycobacterium abscessus; Mycobacterium avium complex; Mycobacterium kansasii; Mycobacterium xenopi; nontuberculous.

PubMed Disclaimer

References

1. Schünemann HJ, Jaeschke R, Cook DJ, et al. ; ATS Documents Development and Implementation Committee An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006; 174:605–14. - PubMed
1. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64:383–94. - PubMed
1. Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol 2013; 66:726–35. - PubMed
1. Griffith DE, Aksamit T, Brown-Elliott BA, et al. ; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367–416. - PubMed
1. Tsukamura M. Diagnosis of disease caused by Mycobacterium avium complex. Chest 1991; 99:667–9. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

Affiliations

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical